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Many, if not most, drug abuse counselors and treatment programs recommend abstinence 
from all psychoactive substances, in part, because of a fear that clients who decrease or 
stop their use of one drug will substitute another. Research to confirm this notion of 
substitution, however, mostly fails to show that abstinence from one drug increases use of 
another. A within-subjects study investigated whether consumption of alcohol and other 
substances changed during marijuana abstinence. Using an ABA design, 28 individuals 
who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-
IV; American Psychiatric Association [APA], 2000) criteria for either cannabis 
dependence or abuse and were not trying to stop their marijuana use completed an 8-day 
baseline period in which they used marijuana and other drugs as usual, then a 13-day 
marijuana abstinence period, and finally a 7-day return-to-baseline period.  Marijuana 
abstinence was induced by a previously-validated contingent compensation schedule.  
Participants called a voicemail system daily to provide self-report of marijuana and 
alcohol use and visited the laboratory twice per week to provide self-report of caffeine, 
cigarette, and other illicit drug use, to complete self-report measures on psychological 
symptoms such as withdrawal and craving, and to submit urine samples to biochemically 
verify marijuana abstinence. Alcohol use significantly increased from a mean of 2.6 
drinks/day (SD=1.0) during the baseline period to 3.0 drinks/day (SD=1.0) during the 
marijuana abstinence period (p=0.03), a 15% increase.  Alcohol use then significantly 
decreased to 2.5 drinks/day (SD=1.3) during the return-to-baseline period (p=0.03), a 
17% decrease. Although alcohol substitution occurred during marijuana abstinence, 
substitution of cigarettes, caffeine, and non-marijuana illicit drugs did not occur.  
Individuals with a diagnosis of past alcohol abuse or dependence substituted alcohol to a 
greater degree (52% increase) than those without this past history (3% increase).  
Increases in alcohol drinks/day correlated with increases in marijuana withdrawal 
discomfort scores and with increases in alcohol craving scores from the baseline to the 
marijuana abstinence period.  Problems related to alcohol did not significantly increase 
from baseline to marijuana abstinence.  This study provides empirical validation of the 
clinical notion of drug substitution and suggests that clinicians’ concerns about drug 
substitution may be valid, but this study’s results need to be replicated in individuals who 
seek treatment for marijuana problems.  Whether substitution reduces the ability to 
abstain from marijuana also needs to be tested.  If alcohol substitution does occur and 
interferes with the ability to quit marijuana, this would be important empirical support for 
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Drug Substitution Background 
 Many, if not most, drug abuse counselors and treatment programs recommend 
abstinence from all psychoactive substances.  One reason for this recommendation is that 
they believe that continued use of other psychoactive drugs can interfere with the ability 
to abstain from the primary drug (Hartel et al., 1995; Moore & Budney, 2001; Sobell, 
Sobell & Kozlowski, 1995; Stuyt, 1997; Wasserman, Weinstein, Havassy & Hall, 1998; 
cf., Budney, Bickel & Amass, 1998; Budney, Higgins & Wong, 1996).  Another reason is 
that they fear that clients who decrease or stop their consumption of one drug will 
substitute a new drug or, more likely, increase use of a concurrently-used drug (Friend & 
Pagano, 2005).  Such substitution could occur to replace the psychoactive effects of the 
abstained drug (Levison, Gerstein & Maloff, 1983), to relieve craving or withdrawal 
(Copersino et al., 2006a), or due to a genetic basis in the overlap between drugs (Agrawal 
& Lynskey, 2006).   In addition, according to behavioral theories of choice (Vuchinich & 
Tucker, 1988), substitution occurs when access to a particular reinforcer, i.e., primary 
substance of abuse, is constrained, and behavior is then reallocated among other available 
reinforcers, i.e., secondary substances of use. Conditioning may be another explanation 
for drug substitution; if individuals use multiple substances simultaneously, the use of 
one substance can act as a cue to elicit the use of another. 
 Research to confirm this notion of substitution, however, mostly fails to show that 
abstinence from one drug increases use of another.  Alcohol and cigarette use are 
moderately to strongly associated (Bien & Burge, 1990; Istvan & Matarazzo, 1984; 
  
 2 
Piasecki, McCarthy, Fiore & Baker, 2008), but there is debate as to whether changing 
either alcohol or cigarette use changes the use of the other.  No significant relations 
between changes in smoking and changes in alcohol drinking were found in the general 
population (Murray, Cribbie, Istvan & Barnes, 2002), nor among individuals seeking 
treatment for alcohol-related problems (Gulliver, Kalman, Rohsenow, Colby, Eaton & 
Monti, 2000) or smoking-related problems (Murray, Istvan & Voelker, 1996); on the 
other hand, smoking cessation was associated with a modest increase in alcohol 
consumption over a 16-year period in World War II male veteran twins (Carmelli, Swan 
& Robinette, 1993).  
 Drug substitution has also been examined in individuals with problems related to 
cocaine and/or opioid use, and conflicting findings have been reported.  Cocaine-
dependent individuals did not change their number of cigarettes smoked during early 
cocaine abstinence (Radzius, Gorelick & Henningfield, 1998), after an outpatient 
treatment program, or at a 9-month follow-up (Patkar, Mannelli, Peindl, Murray, Meier & 
Leone, 2006).  Primary heroin users seeking treatment in the Australian Treatment 
Outcome Study did not show evidence of drug (i.e., cocaine, other opioids) substitution 
after reducing their heroin use (Darke, Williamson, Ross & Teesson, 2006).  Multiple 
studies of methadone maintenance treatment for primary heroin users suggest that 
changing heroin use increases cigarette use (Conner, Stein, Longshore & Stacy, 1999), 
decreases alcohol and cocaine use (Maremmani et al., 2007), and has no effect on 
cannabis use (Epstein & Preston, 2003).  However, in non-treatment studies, cocaine 
users reported marijuana and sedatives as substitutes for cocaine (Jofre-Benet & Petry, 
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2008), and heroin users reported marijuana and alcohol as substitutes for heroin (Petry & 
Bickel, 1998).   
 While research on drug substitution has focused mostly on alcohol, cigarettes, 
cocaine, and heroin, caffeine may also act as a substitute for other substances, notably 
cigarettes and alcohol.  Caffeine is moderately related to tobacco (Istvan & Matarazzo, 
1984) and may be associated with alcohol (Swan, Carmelli & Cardon, 1996).  After 
alcohol detoxification, individuals reported an increase in coffee use (Aubin, Laureaux, 
Tilikete & Barrucand, 1999), and after coffee-drinkers quit smoking cigarettes, they 
consumed more coffee than nonsmokers (Swanson, Lee & Hopp, 1994). 
 
Drug Substitution for Particular Subgroups 
 Despite these general patterns that mostly do not find drug substitution, it is 
possible that substitution does occur for subgroups of individuals.  Examination of these 
subgroups mostly shows that those with moderate, as opposed to heavy, use of secondary 
substances are more likely to report drug substitution.   In two studies of treatment-
seekers for alcohol and substance use problems, cigarette use increased when those who 
were moderate smokers prior to treatment admission abstained, while cigarette use 
decreased for those who were classified as heavy smokers (Aubin et al., 1999; Harris, 
Best, Man, Welch, Gossop & Strang, 2000).  Furthermore, among non-crack users of 
opioids at treatment intake, 22% substituted crack for opioids during the 4-5 years post-
treatment, while users of both opioids and crack at treatment intake did not substitute 
crack after decreasing their opioid use.  Of this 22%, two-thirds actually initiated crack 
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use, i.e., had never tried it during their drug use history (Gossop, Marsden, Stewart & 
Kidd, 2002).  On the other hand, opioid users with high levels of cocaine use at treatment 
entry were most likely to substitute cocaine use for opioids during methadone 
maintenance treatment, in comparison to two groups of opioid users who did not use 
cocaine heavily at treatment entry (Bovasso & Cacciola, 2003).  
 
Drug Substitution in Marijuana Users 
Drug substitution has not been adequately examined in primary users of 
marijuana, although most users of marijuana also use other drugs (World Health 
Organization, 1997), especially alcohol (Hughes, Day, Marcantonio & Torpy, 1997; 
Norton & Colliver, 1988).  Secondary abuse of alcohol was reported by 57% of treatment 
admissions for primary marijuana abuse between 1994 and 1999 (SAMHSA, 1999).  In a 
retrospective study, at least half of current cannabis users stated that in past quit attempts, 
they increased their use of alcohol and tobacco (Copersino et al., 2006b).  Prospective 
trials of outpatient treatments for adult marijuana dependence, however, reported 
discrepant results. One study reported a significant increase in the posttreatment 
frequency of alcohol use and related problems (Stephens, Roffman & Simpson, 1994), 
while others found either a reduction in alcohol use (Stephens, Roffman & Curtin, 2000) 
or no significant change in alcohol use following treatment for marijuana use (Budney, 
Higgins, Radonovich & Novy, 2000; The Marijuana Treatment Project Research Group, 
2004).  In several prospective non-treatment studies, marijuana abstinence did not change 
the use of alcohol, tobacco, and other drugs (Budney, Hughes, Moore & Novy, 2001; 
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Budney, Moore, Vandrey & Hughes, 2003; Haney, Hart, Vosburg, Nasser, Bennett, 
Zubaran, et al., 2004; Kouri & Pope, 2000).   
The above findings on drug substitution in marijuana users should be interpreted 
with caution for several reasons.  First, retrospective studies potentially have recall or 
rationalization biases.  Second, the prospective studies excluded participants who were 
frequent alcohol users and included non-alcohol users, thereby decreasing their 
sensitivity to detect a change in alcohol use.  Third, the treatment studies are confounded 
by treatment instructions to avoid drug substitution; the non-treatment studies are 
confounded by explicit instructions to not change alcohol use (Budney et al., 2001; 
Budney et al., 2003); and inpatient studies are confounded by participants not having 
access to alcohol (Haney et al., 2004).  Fourth, alcohol use was not a major dependent 
variable in these studies and, thus, measurement of alcohol use was less-than-optimal; 
e.g., several studies measured alcohol use in a single self-report of the past 90 days.  In 
summary, an adequate test of whether marijuana abstinence changes alcohol use has not 
been accomplished.  
This dissertation attempted to overcome the above-listed problems by 
prospectively examining possible drug substitution, by recruiting regular marijuana users 
who use alcohol moderately, by instructing participants to use alcohol as they wish, and 
by assessing alcohol use on a daily basis.  Although the study was designed to detect the 
substitution of alcohol for marijuana, whether marijuana abstinence changed the use of 





Design   
 A within-subjects study investigated whether consumption of alcohol and other 
substances changed during marijuana abstinence. Using an ABA design, 28 individuals 
who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-
IV; American Psychiatric Association [APA], 2000) criteria for either cannabis 
dependence or abuse and were not trying to stop their marijuana use completed an 8-day 
baseline period in which they used marijuana and other drugs as usual, then a 13-day 
marijuana abstinence period, and finally a 7-day return-to-baseline period.  Marijuana 
abstinence was induced by a previously-validated contingent compensation schedule 
(Budney et al., 2003).  Participants called a voicemail system (Hughes, Peters, Callas, 
Budney & Livingston, 2008) daily to provide self-report of marijuana and alcohol use.  
Participants visited the laboratory twice per week to provide self-report of caffeine, 
cigarette, and other illicit drug use, to complete self-report measures on psychological 
symptoms such as withdrawal and craving, and to submit urine samples to biochemically 
verify marijuana abstinence.   
 
Participants 
 Participants in the Burlington, Vermont area were recruited via advertisements in 
an alternative newspaper, newspapers of local universities, and a local radio station.  
Advertisements specified that “regular” marijuana users who did not plan to stop their 
marijuana use were sought for a non-treatment study.  Individuals were deemed eligible 
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to participate if they: a) were 18 years of age or older; b) smoked marijuana at least once 
per day on 25 of the past 30 days; c) used marijuana at this rate for at least 6 months; d) 
met DSM-IV (APA, 2000) criteria for current (i.e., within the past 12 months) cannabis 
dependence or abuse; e) for males, currently consumed between 3 and 16 standard drinks 
of alcohol per week and for females, currently consumed between 3 and 12 standard 
drinks of alcohol per week; f) provided a urine sample at the initial assessment that tested 
positive for tetrahydrocannabinol (THC), the primary psychoactive component of 
marijuana (Huestis, 2005); and g) were willing to abstain from marijuana for two weeks.  
Individuals were excluded if they: a) met DSM-IV (APA, 2000) criteria for current (i.e., 
within the past 12 months) alcohol or other substance abuse or dependence (not including 
caffeine and nicotine); b) were currently taking psychotropic medication that interacted 
with alcohol use or its effects; c) planned to change substance use, diet, or activity in the 
next four weeks; d) were actively seeking treatment for substance-related or psychiatric 
problems; e) reported a significant change (increase or decrease of 25%) in the amount of 
marijuana or other drugs used in the previous month; f) were currently incarcerated or 
their legal status was such that they may be incarcerated during enrollment in the study; 
or g) had urgent drug-related or psychiatric problems (e.g., abuse of others or suicidal 
ideation). 
 Marijuana users who met diagnostic criteria for current cannabis dependence or 
abuse were recruited because most treatment-seekers are dependent users (SAMHSA, 
1999).  Participants could report current alcohol problems but could not fulfill diagnostic 
criteria for current alcohol dependence or abuse. Participants who consumed between 3 
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and 16 (for males) or between 3 and 12 (for females) standard drinks of alcohol each 
week were included to avoid ceiling and floor effects that would prevent seeing an 
increase or decrease in alcohol use during marijuana abstinence.  Furthermore, these are 
the maximums for moderate drinking, according to empirically-based guidelines 
(Sanchez-Craig, Wilkinson & Davila, 1995).  Individuals who planned to change their 
alcohol or substance use were excluded in order to avoid changes in alcohol use that were 
specifically done to aid in marijuana abstinence.  Recruiting individuals who were not 
trying to change their marijuana use allowed an ethical return-to-baseline condition; 
however, this strategy minimized external validity to those who are actively trying to quit 
marijuana.  
 
Sample Size  
In a power analysis to determine a sample size adequate to detect a significant 
change in alcohol consumption during marijuana abstinence, a significant change was 
defined as being an increase or decrease of 30%-50% of baseline alcohol use.  Although 
an increase in alcohol use (i.e., drug substitution) was the main outcome of interest, a 
decrease in use was also of interest; thus, two-tailed tests were used. Data from Budney et 
al. (2003) and from a preliminary study of tobacco smokers (Peters, Hughes, Callas & 
Solomon, 2007) reported within-subject correlations of alcohol consumption of 0.6 and 
0.8, respectively.  Scenarios with within-subject correlations of 0.6 and 0.8 were run, 
with changes in alcohol use of 30% and 50%, and with power of 0.80.  In all scenarios, 
alpha was set at 0.05 (two-tailed). A sample size of 28 was chosen because this was 
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 Screening and Consent 
 Individuals were screened for eligibility via telephone.  Those eligible were read a 
brief description of the study, and those interested visited the laboratory to provide 
written informed consent. To decrease experimenter demand, participants were not 
informed that the focus of the study was on drug substitution; instead, the stated purpose 
was to determine how difficult individuals find it to abstain from marijuana for two 
weeks.  Immediately after providing informed consent to participate, individuals provided 
a breath alcohol level (BAL; Intoximeters, Inc., St. Louis, MO) sample to measure recent 
alcohol intake and verify that they were capable of providing consent.  No participant 
submitted a positive BAL sample.   
 
 Initial Assessment 
 The author, a doctoral student in clinical psychology previously trained in the 
Structured Clinical Interview Diagnostic (SCID; First, Spitzer, Gibbon, & Williams, 
1995) for the DSM-IV (APA, 2000), administered the following modules:  alcohol use 
disorders, substance use disorders, mood disorders, anxiety disorders, and psychotic 
disorders.  Five individuals met criteria for a current Axis I disorder; the interviewer 
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informed them of their diagnosis and ineligibility for the study, and referred them to 
treatment.  Those participants who appeared to be eligible after the interview then 
completed self-report measures on demographics, current and past drug use history, and 
nicotine dependence (i.e., Fagerstrom Test of Nicotine Dependence [FTND]; Heatherton, 
Kozlowski, Frecker & Fagerstrom, 1991).  They also completed the following self-report 
measures on psychological symptoms related to substance use: 
 
1) Marijuana withdrawal:  The Marijuana Withdrawal Checklist (MWC; Budney et al., 
2003) is a 31-item checklist of symptoms of marijuana withdrawal, as well as general 
symptoms (e.g., stuffy nose) to estimate over-endorsement due to experimenter demand 
or expectancy effects.  Individuals rate the severity of symptoms on a 4-point scale 
(0=not at all, 1=mild, 2=moderate, 3=severe).  Prior studies have shown this measure to 
be sensitive to the effects of marijuana abstinence (Budney et al., 1999; Budney et al., 
2001; Budney et al., 2003).  A Withdrawal Discomfort Score (WDS) is computed by 
summing severity ratings of twelve items that previous studies documented as possible 
withdrawal symptoms: aggression, anger, decreased appetite, depressed mood, 
irritability, nervousness/anxiety, restlessness, shakiness, sleep difficulty, stomach pains, 
strange dreams, and sweating (Budney et al., 2003).  The range of possible Withdrawal 
Discomfort Scores is 0-36.  
 
2)  Marijuana craving:  The Marijuana Craving Questionnaire (MCQ; Heishman, 
Singleton & Liguori, 2001) is a 45-item questionnaire that is a valid and reliable 
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instrument for assessing marijuana craving in individuals not seeking drug abuse 
treatment.  The original MCQ required items to be rated on a 7-point Likert scale from 
“strongly disagree” to “strongly agree,” but the version used in this study had each item 
rated as “true” or “false,” with a point value of 1 corresponding to “true” and 0 
corresponding to “false.”  Subscales include compulsivity, emotionality, expectancy, and 
purposefulness.   The range of possible scores for the version used in this study is 0-45.  
 
3)  Marijuana problems:  The Cannabis Problems Questionnaire (CPQ; Copeland, 
Gilmour, Gates & Swift, 2005) is a list of 27 possible problems related to marijuana use 
that are scored as dichotomous yes/no responses.  The CPQ is a valid, reliable, and 
sensitive measure of cannabis-related problems and provides subscale scores for social, 
psychological, and physical problems.  The range of possible scores is 0-27.  
  
4)  Alcohol craving:  The Penn Alcohol Craving Scale (PACS; Flannery, Volpicelli & 
Pettinati, 1999) is a five-item measure that includes questions about the frequency, 
intensity, and duration of craving and asks for an overall rating of craving for alcohol.  
Individuals rate their responses on a scale of 0 to 6, and the range of possible scores is 0-
30.   
 
5)  Alcohol problems:  The Short Index of Problems (SIP; Feinn, Tennen & Kranzler, 
2003) is a short form of the Drinker Inventory of Consequences (Miller, Tonigan & 
Longabaugh, 1995).  The SIP consists of 15 questions about problems related to alcohol 
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use with response choices of “yes” and “no,” and it has good internal consistency, good 
concurrent validity, and adequate stability.  The range of possible scores is 0-15.  
 
6)  Cigarette craving:  The Brief Questionnaire of Smoking Urges (QSU; Sanderson Cox, 
Tiffany & Christen, 2001; Tiffany & Drobes, 1991) consists of ten items with two 
subscales: one that reflects a strong desire and intention to smoke, and one that reflects 
anticipation of relief from negative affect with an urgent desire to smoke.  Individuals 
rate items on a 4-point Likert scale from “strongly disagree” to “strongly agree.”  The 
range of possible responses is 10-40.    
 
7)  Mood disturbance:  The brief version of the Profile of Mood States (POMS; McNair, 
Lorr & Droppleman, 2003) is a 30-item list of mood states.  Individuals rate the 
frequency of experiencing each mood state on a scale of 0 (“not at all”) to 4 
(“extremely”).  This measure provides six subscale scores:  tension, depression, anger, 
vigor, fatigue, and confusion.  A total mood disturbance score is calculated by summing 
the subscale scores of tension, depression, anger, fatigue, and confusion and then 
subtracting the vigor subscale score.  The range of possible total scores is -20 to +100.   
 
 Participants provided a urine sample that was tested for THC onsite via Enzyme 
Multiplied Immunoassay Technique (EMIT; Microgenics MGC 240 EMIT Benchtop 
Analyzer, Thermo Scientific, Fremont, CA).  Results greater than 50 ng/mL signified that 
individuals had used marijuana within the past 1-2 days (Huestis, Mitchell & Cone, 
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1995).  Only participants who provided a positive urine sample were included in the 
study.  This sample was also tested for pregnancy in females; no female participant 
provided a positive sample.  Eligible participants were scheduled for their first laboratory 
visit of the baseline period.   
   
 Baseline Period (8 days) 
 Figure 1 presents the experimental timeline of the study.  To minimize the effect 
of specific days on substance use and psychological symptom measures, all participants 
began the study on a Thursday.  Female participants began on the Thursday following the 
onset of menses.  Participants were instructed to use their usual amounts of marijuana, 
alcohol and other substances during the baseline period.   
 Participants were instructed to call a voicemail system when they awoke each 
morning to report the number of sessions in which they used marijuana and standard 
drinks of beer, wine, and liquor they consumed the previous day. Participants were 
informed that a single marijuana smoking session represented one sitting in which they 
used marijuana (i.e., smoking one marijuana cigarette in two separate sittings equaled 
two sessions).  They were further informed that a standard drink of alcohol is 12 ounces 
of beer, 5 ounces of wine, and 1.5 ounces of liquor (U.S. Department of Health and 
Human Services, 2007). To maximize confidentiality, participants were given unique 
study identification numbers and directed to identify themselves only with this number in 
their daily calls.  They began their calls the morning after the first laboratory visit.  The 
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study coordinator received the voicemail messages at noon each day and reminded any 
participant who did not provide a voicemail to call the system immediately.  
 Participants visited the laboratory again on Monday and Thursday. Timeline 
Follow-Back (TLFB; Sobell & Sobell, 1992) procedures gathered data on participants’ 
use of caffeine, cigarettes, and non-marijuana illicit drugs on each day since the previous 
laboratory visit.  Separate questions were asked about caffeine use (i.e., consumption of 
coffee, tea, or caffeinated soda) (Hughes & Oliveto, 1997), and responses were coded 
into standard drinks, where a standard drink equaled 6 ounces of brewed coffee, 24 
ounces of tea, and 48 ounces of soda (Barone & Grice, 1994). Participants reported 
number of tobacco cigarettes smoked, as well as pharmacological class (e.g., stimulants, 
sedatives) and number of sessions using any non-marijuana illicit drugs.  Perseus Survey 
Solutions (Perseus Development Corporation, Braintree, MA), an Internet-based survey 
system, collected participants’ responses to the seven self-report measures described in 
the “Initial Assessment” section.  Participants were instructed to provide responses based 
on their experiences since the prior laboratory visit.  BAL samples (Intoximeters, Inc., St. 
Louis, MO) to measure recent alcohol intake and breath carbon monoxide (CO; Bedfont 
Scientific Ltd., Rochester, UK) samples to measure recent cigarette smoking (i.e., within 
the past 24 hours; Benowitz, Jacob, Ahijevych, Jarvis, Hall, LeHouezec, et al., 2002) 
were collected. Body weight was obtained without shoes and heavy clothing. 
 On the last visit of this period, participants provided a urine sample to establish 
their baseline level of marijuana use and were then instructed to abstain completely from 
marijuana beginning the next morning. Participants were only directed to use alcohol, 
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cigarettes, caffeine, and non-marijuana drugs “as they wish” so their use of other 
substances could naturally increase, decrease, or stay the same.  They were informed of 
the contingent payment system to reinforce abstinence.  
 
 Abstinence Period (13 days) 
 The abstinence period began on a Friday and lasted 13 days in order to encompass 
two weekends, assuming that participants would be more likely to consume alcohol on 
weekend-days than weekdays.  Participants continued making daily calls each morning.  
At Monday and Thursday laboratory visits, participants underwent the same assessments 
described in the “Baseline Period” section.  Additionally, they provided urine samples at 
all visits to verify abstinence from marijuana.  
 
 Compensation to Induce Abstinence 
 In order to obtain a high rate of compliance with the 13-day abstinence 
requirement, participants were contingently compensated with an escalating schedule of 
reinforcement.  This compensation schedule has been used effectively in prior studies of 
marijuana abstinence (e.g., Budney et al., 2003).  Participants earned vouchers if urine 
specimens indicated no recent marijuana use (see “Urine Sample Collection and Analytic 
Methods” below for the definition of “no recent marijuana use”). The value of the initial 
voucher given for abstinence from marijuana was $15, and each subsequent voucher for 
abstinence increased in value by $5 (i.e., to $20, then $25, then $30).  The seven 
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participants who either self-reported marijuana use during the abstinence period or 
provided samples that did not verify abstinence were discontinued and received the 
amount they earned to that point.  
 
 Return-to-Baseline Period (7 days) 
 Participants were informed that after the last visit of the abstinence period, they 
could return to marijuana use.  However, in order to not coerce participants to engage in 
an illegal behavior, participants were told that they could remain in the study whether or 
not they returned to use.  Participants continued with daily calls and Monday and 
Thursday laboratory visits.  Participants provided a urine sample at the first visit of this 
period to confirm reinstatement of marijuana use.  At the last visit, the study coordinator 
debriefed participants about the primary aims of the study and interviewed them about 
reasons why their use of other drugs did or did not change.   
 
 Compensation for Completing Study Procedures  
 The value of the voucher for completing the initial assessment was $15, and the 
value for each laboratory visit was $5.  The value of the voucher for completing each 
daily call was $1.  Participants who completed all scheduled laboratory visits and daily 
calls and who abstained from marijuana for every day of the abstinence period were 
compensated a bonus of $50.  Thus, the total maximal compensation was $253 in 
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vouchers.  Vouchers were redeemed for retail goods designated by participants; no cash 
was provided.   
    
Urine Sample Collection and Analytic Methods 
 Participants provided six urine samples throughout the study:  at the last visit of 
the baseline period, at each visit of the marijuana abstinence period, and at the first visit 
of the return-to-baseline period.  A temperature gauge on the collection container verified 
the validity of the sample (i.e., the temperature within 3-minutes post-collection must 
have been between 90 and 100 degrees Fahrenheit) (Dominion Diagnostics, Providence, 
RI).  Each sample was split into two samples: one was mailed overnight to Dominion 
Diagnostics (Providence, RI) for immediate analysis, and one was saved for later analysis 
or in case of errors.  Results from each visit were available on Dominion Diagnostics’ 
(Providence, RI) password-protected website before the subsequent visit.  
 Marijuana use and abstinence were quantitatively measured by enzyme 
immunoassay (EIA), with positive results confirmed by Gas Chromatography/Mass 
Spectrometry (GC/MS) (Dominion Diagnostics, Providence, RI).  GC/MS levels of 11-
nor-9-carboxy-∆9-tetrahydrocannabinol (THCCOOH), the primary marijuana metabolite, 
were normalized to urine creatinine concentration to obtain a metabolite/creatinine ratio 
(Budney et al., 2003; Huestis & Cone, 1998). According to Huestis (2005), normalization 
of the THCCOOH concentration to the urine creatinine concentration aids in the 
differentiation of new vs. prior cannabis use, reduces the variability of drug measurement 
due to urine dilution, and facilitates interpretation of consecutive urine drug test results.  
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Marijuana use during the baseline period was validated if the EIA result for cannabinoids 
was greater than 25 ng/mL (Dominion Diagnostics, Providence, RI).  Abstinence was 
validated by examining the metabolite/creatinine ratio because this ratio can reliably 
document short periods of marijuana abstinence (Huestis & Cone, 1998). An empirically-
derived algorithm developed by Huestis & Cone (1998) has been used in previous studies 
to validate marijuana abstinence (e.g., Budney et al., 2003), in which abstinence is 
confirmed if the metabolite/creatinine ratio on any day does not increase by more than 
50% from the ratio obtained on the previous day.  Because of financial constraints, we 
could only collect samples twice-weekly and thus, this algorithm was not applicable.  We 
reasoned that with abstinence of three to four days, there should be a decrease in the 
metabolite/creatinine ratio from one visit to the next and used this as the abstinence 
criterion (Dominion Diagnostics, Providence, RI).  An increase in the 
metabolite/creatinine ratio from the last visit of the abstinence period to the first sample 
of the return-to-baseline visit confirmed return to marijuana use.   
 Urine samples were also tested for cotinine, the primary nicotine metabolite 
(Benowitz et al., 2002), via EIA to determine cigarette use.  The cut-off for a positive 
cotinine result was 500 ng/mL (Dominion Diagnostics, Providence, RI).  Biochemical 
validation of alcohol use was considered, but biomarkers such as carbohydrate-deficient 
transferrin (CDT) indicate alcohol abuse and long-term alcohol consumption rather than 
short-term consumption (Bortolotti, De Paoli & Tagliaro, 2006).  Due to financial 
constraints, quantitative analysis of illicit drugs and caffeine was not possible.  
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Data Analysis  
 Among the 28 individuals who completed the study, missing data were minimal:  
24 of 784 days (3%) of daily call data were missing, and 6 of 252 (2%) laboratory visit 
data (i.e., TLFB and biochemical data) were missing.  All missing visit data occurred 
during the return-to-baseline period when three participants unexpectedly left the 
Burlington area.  There were no missing data from the questionnaires completed at 
laboratory visits because Perseus Survey Solutions (Perseus Development Corporation, 
Braintree, MA) did not allow missing responses. 
Because most data were contained in written records, a technician in the 
University of Vermont Department of Medical Biostatistics double-entered written 
records into Microsoft Excel.  Self-report data collected at laboratory visits were 
downloaded from Perseus Survey Solutions (Perseus Development Corporation, 
Braintree, MA) to Microsoft Excel.  Data were screened for missing and illogical values 
and outliers.  Missing data were imputed using the mean of adjacent values when 
possible, and last point carried forward when not possible (i.e., when a missing value 
occurred on the last day or visit of the study). Most analyses were performed with SPSS 
16.0 (Chicago, IL), but analyses regarding residual data were examined with SAS 
(version 9, SAS Institute, Cary, NC).   
 Sundays through Thursdays were defined as weekdays and Fridays and Saturdays 
as weekend-days because substance use often occurs in the evenings of these days.  
Because participants tended to consume more alcohol on weekend-days (M=4.4 
[SD=1.5]) than weekdays (M=2.2 [SD=1.0], t(27)=8.30, p<0.01), mean alcohol 
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drinks/day of each period were adjusted to ensure the same ratio of weekdays to 
weekend-days occurred in each of the three periods.  For example, during the baseline 
period, the ratio of weekdays to weekend-days was 3:1, but during the marijuana 
abstinence period, the ratio was 9:4.  With a ratio of 9:4, the mean alcohol drinks/day 
during the abstinence period may have been inflated in comparison to the baseline period 
because of more weekend-days during abstinence than during baseline.  To create a 
weekday to weekend-day ratio during abstinence that was similar to the ratio during 
baseline, the desired ratio of weekdays to weekend-days during the abstinence period was 
12:4.  Thus, each weekday value of alcohol drinks during the abstinence period needed to 
be weighted, or multiplied, by 1.33 (i.e., 12/9).  With this weighting procedure, there 
were three additional weekdays accounted for during abstinence, so the new total alcohol 
drinks during the abstinence period were divided by 16 days to arrive at mean alcohol 
drinks/day.  A similar weighting procedure was undertaken for the return-to-baseline 
period, where the original ratio of weekdays to weekend-days was 5:2.    
 The major specific aim was to examine whether there were changes in use of 
alcohol during marijuana abstinence.  A repeated-measures analysis of variance 
(ANOVA) tested differences in weighted mean number of alcohol drinks per day among 
the three periods, with period as the within-subjects factor.  The following two a priori 
comparisons were examined in paired-samples t-tests: a) mean alcohol drinks/day in the 
baseline period vs. that in the abstinence period, and b) mean alcohol drinks/day in the 
abstinence period vs. that in the return-to-baseline period.  Similar repeated-measures 
ANOVAs and follow-up comparisons were conducted for other alcohol use outcomes, 
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such as weekday and weekend-day mean alcohol drinks/day and mean drinks/day only on 
days when individuals consumed at least one drink of alcohol. Because sphericity 
assumptions were often violated in the repeated-measures analyses, main effects for 
period are reported using Huynh-Feldt tests, and percent of variance accounted for 
provides a relative magnitude of the differences among the three periods.  Wilcoxon tests 
examined differences in percentage of binge-drinking episodes (for males, consumption 
of 5+ drinks on one day and for females, consumption of 4+ drinks on one day [Wechsler 
& Austin, 1998]) and percentage of days on which individuals drank at least one alcohol 
drink.  In order to examine the 13 days of the marijuana abstinence period with a similar 
number of days in the Wilcoxon tests, the baseline and return-to-baseline periods were 
combined and then contrasted with the marijuana abstinence period.  Mean percentages 
in the baseline and return-to-baseline periods did not significantly differ for either 
outcome (mean percent of binge-drinking episodes:  23% [SD=15%] in baseline and 23% 
[SD=17%] in return-to-baseline, z=-0.24, p=0.81; mean percent of days on which 
individuals drank at least one alcohol drink:  69% [SD=19%] in baseline and 68% 
[SD=26%] in return-to-baseline, z=-0.42, p=0.68).  
 A secondary aim was to examine whether there were changes in use of substances 
other than alcohol during marijuana abstinence.  To examine whether cigarette or 
caffeine use changed, similar ANOVAs and follow-up comparisons tested for similar 




   Another secondary aim was to examine changes in psychological symptoms 
during marijuana abstinence.  Because these data were collected at laboratory visits and 
because differing number of visits occurred during each period, mean values were 
computed for each period in the following manner: the baseline period encompassed data 
from the first three laboratory visits, the marijuana abstinence period encompassed the 
next four laboratory visits, and the return-to-baseline period encompassed the final two 
laboratory visits.  Repeated-measures ANOVAs and follow-up comparisons were 
conducted to examine changes in psychological symptoms across the three study periods. 
Overall questionnaire scores and subscale scores, if applicable, for marijuana WDS, 
marijuana craving, marijuana problems, alcohol craving, alcohol problems, cigarette 
craving, and mood disturbance were examined. 
 Hypothesized moderators that might influence the effect of marijuana abstinence 
on alcohol use included demographic variables (e.g., sex, age, race, education status, and 
employment status) and substance use history variables collected at the initial assessment.    
For example, possible moderators related to substance use history included: 
1. current cannabis diagnosis (i.e., dependence vs. abuse); 
2. diagnosis of past alcohol abuse or dependence vs. no diagnosis;  
3. diagnosis of past non-marijuana substance dependence vs. no diagnosis; 
4. marijuana problems during the baseline period;  
5. marijuana craving during the baseline period; 
6. alcohol drinks/day during the baseline period; 
7. alcohol problems during the baseline period; and  
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8. alcohol craving during the baseline period.   
Another possible moderator was overall mood disturbance score during the baseline 
period.  All possible moderators of the alcohol substitution effect were investigated by 
inspecting the interaction between these variables and the main effect for period in the 
repeated-measures ANOVAs.  In order to graphically inspect possible interactions, 
continuous moderating variables (#4-8 listed above) were recoded into categorical 
variables by performing median splits.  The interaction between these categorical 
moderating variables and the period effect was then statistically examined using Wilks’ 
Lambda tests for between-group comparisons.  
 Hypothesized mediators of the effect of marijuana abstinence on alcohol use 
included marijuana withdrawal discomfort and other psychological symptoms collected 
at laboratory visits (see #1-7 of “Initial Assessment” section).  Formal mediational tests 
were not conducted because of concern about small sample size.  Thus, for those 
psychological symptoms that significantly changed from baseline to marijuana 
abstinence, we examined correlations between such changes and changes in alcohol 
drinks/day from baseline to marijuana abstinence.  Because the small sample size may 
have precluded statistically significant results, trends were also examined graphically.  
 To examine the time course of any substitution effect during marijuana 
abstinence, i.e., whether alcohol use significantly increased for the first few days of 
abstinence but then returned to normal, we computed residual alcohol use scores.  
Residual scores reflected the difference between alcohol drinks/day that would be 
expected based on the baseline and return-to-baseline periods vs. actual observed alcohol 
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drinks/day during the marijuana abstinence period.  Because the mean alcohol drinks/day 
during the baseline (M=2.6 [SD=1.0]) and return-to-baseline (M=2.5 [SD=1.3]) periods 
were not significantly different (t(27)=0.29, p=0.78), we used data from both periods to 
compute expected number of alcohol drinks/day. To control for weekday vs. weekend-
day alcohol use variability, we calculated residuals separately for a weekday and a 
weekend-day.  We then calculated residual alcohol scores by subtracting the expected 
number of drinks for weekdays and weekend-days during the two baseline periods from 





 Figure 2 presents a flowchart of recruitment and retention of participants.  Of 420 
individuals who responded to advertisements, 312 (74%) were able to be reached by 
telephone for screening for inclusion into the study, and 245 (78% of those screened) 
were ineligible.  The most common reasons for ineligibility included: a) currently 
consumed more than 16 alcohol drinks/week for males or 12 drinks/week for females 
(38%); b) currently consumed less than 3 alcohol drinks/week (33%); and c) currently 
used marijuana on fewer than 25 of the past 30 days (27%).     
 Of the 67 individuals who were eligible, 18 (27%) were not interested in 
participating.  Of the 49 who were interested, 11 (22%) were not eligible after the initial 
in-person assessment; the most common reason for ineligibility was meeting diagnostic 
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criteria for current alcohol or substance use disorder (n=4, 36% of those not eligible).  Of 
the 38 individuals who were eligible after the initial assessment, two were no longer 
interested and did not begin the study.  36 participants enrolled in the study, and 29 
participants completed the study.  Of the seven participants who did not complete the 
study, six self-reported marijuana use during the marijuana abstinence period, and one 
participant cited personal reasons for withdrawing during the baseline period. Of the 29 
participants who completed the study, two lived together and thus may not have provided 
independent data; the urinalysis testing of one of these individuals showed lower than 
expected creatinine-normalized THCCOOH levels during the baseline period, so she was 
omitted from data analysis.  Thus, 28 participants were included in the analysis.  
 
Sample Characteristics 
 Table 2 presents demographic and substance use characteristics for the 28 
individuals who completed the study and were included in data analysis.  Because the 
findings from this study may have relevance to individuals seeking treatment for 
marijuana dependence, the current sample was compared to treatment-seeking, daily 
users in the largest marijuana treatment study – The Marijuana Treatment Project (MTP; 
The Marijuana Treatment Project Research Group, 2004).  Our participants were younger 
(23 vs. 36 years); more likely to be male (75% vs. 68%), Caucasian (93% vs. 69%), and 
unmarried (100% vs. 60%); and less likely to be employed full-time (36% vs. 69%).  
However, many were full-time students (21%).   
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 Participants currently used marijuana almost every day and almost three times 
each day, rates similar to those in the MTP (The Marijuana Treatment Project Research 
Group, 2004).  Nineteen participants (68%) met DSM-IV (APA, 2000) criteria for current 
cannabis dependence, and nine (32%) met criteria for current cannabis abuse.  
Participants currently drank about ten alcohol drinks/week and reported binge-drinking 
(Wechsler & Austin, 1998) on three days of the past month.  Even though participants 
had to currently use at least three alcohol drinks/week, five participants (18%) met DSM-
IV (APA, 2000) criteria for past alcohol abuse, and two (7%) met criteria for past alcohol 
dependence.  
 Most participants (n=18, 64%) drank coffee regularly.  These participants drank 
coffee about six days/week (M=5.9, SD=2.0) and consumed about two cups of coffee/day 
(M=2.1, SD=0.9).  Eight participants (29%) drank tea regularly.  They drank tea less than 
4 days/week (M=3.6, SD=2.1) and consumed less than 2 drinks/day (M=1.7, SD=0.9).  
Ten participants (36%) drank soda regularly.  They drank soda on less than 3 days/week 
(M=2.6, SD=1.8) and consumed about 1 soda drink/day (M=1.3, SD=0.5).  This caffeine 
consumption appears similar to that for individuals of the state of Vermont (Hughes & 
Oliveto, 1997).   
 A minority of participants (n=7, 25%) currently smoked cigarettes; six of these 
consumed 1-5 cigarettes per day, while one smoked 20 cigarettes/day.  This consumption 
is less than that for Vermont smokers (mean of 14.7 cigarettes/day; Vermont Department 
of Health, 2008a). Their mean FTND score was 1.1 (SD=1.9), compared to 3.6 for 
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Vermont smokers (Vermont Department of Health, 2008b).  No information was 
gathered regarding whether participants used cigarettes on a less-than-daily basis.  
 Participants reported infrequent current use of illicit drugs other than marijuana, 
similar to those of the MTP (The Marijuana Treatment Project Research Group, 2004).  
Two participants used stimulants (e.g., cocaine) once in the past month, and two 
participants used hallucinogens (e.g., lysergic acid diethylamide) once in the past month.  
Three participants (11%) met DSM-IV criteria for past substance dependence (one 
cocaine, one opioid, one both cocaine and opioid).   
 
Marijuana Use  
 The 28 designated participants used marijuana on a mean of 7.8 (SD=0.5) of the 8 
days (98%) of the baseline period and 5.8 (SD=1.8) of the 7 days (83%) of the return-to-
baseline period.  Self-reported marijuana use (i.e., sessions/day) significantly changed 
across the three periods of the study (F(2,54)=84.80, p<0.01) (Table 3). Marijuana use 
significantly decreased from a mean of 2.9 sessions/day (SD=1.3) during the baseline 
period to 0 sessions/day (SD=0.0) during the marijuana abstinence period (t(27)=12.01, 
p<0.01), and use then significantly increased to 2.2 sessions/day (SD=1.3) during the 
return-to-baseline period (t(27)=-8.94, p<0.01).  Marijuana use significantly differed 
between the two baseline periods (t(27)=3.21, p<0.01), with use greater in the baseline 
period than in the return-to-baseline period.  Creatinine-normalized THCCOOH levels 
significantly changed across the three periods (p<0.01; Figure 3).  Mean THCCOOH 
levels significantly decreased from the baseline period (350.1 [SD=432.5]) to the 
  
 28 
marijuana abstinence period (36.7 [SD=37.6]; t(25)=3.96, p<0.01), and mean levels 
significantly increased from the marijuana abstinence period to the return-to-baseline 
period (127.5 [SD=123.5]; t(27)=-4.39, p<0.01).  
 Marijuana withdrawal discomfort scores significantly changed across the three 
periods of the study (p<0.01), accounting for 36.1% of the variance.  Mean WDS 
significantly increased from the baseline period (2.9 [SD=2.9]) to the marijuana 
abstinence period (5.1 [SD=4.0]; t(27)=-3.98, p<0.01), and scores significantly decreased 
from the marijuana abstinence period to the return-to-baseline period (2.5 [SD=2.7]; 
t(27)=4.44, p<0.01). Participants’ weight (in pounds) significantly changed across the 
three periods of the study (F(2,54)=10.37, p<0.01).  Weight significantly decreased from 
the baseline period (M=163.4, SD=32.9) to the marijuana abstinence period (M=161.3, 
SD=32.2, t(27)=5.13, p<0.01), and it then significantly increased from the abstinence 
period to the return-to-baseline period (M=162.5, SD=32.2, t(27)=-2.39, p=0.02). 
 Overall marijuana craving scores did not significantly change across the three 
periods of the study (p=0.73), nor did scores change on any marijuana craving subscales 
(compulsivity: p=0.94; emotionality: p=0.27; expectancy: p=0.20; and purposefulness: 
p=0.29).  Overall marijuana problem scores significantly changed across the three periods 
of the study (p<0.01), accounting for 38.1% of the variance.  Mean marijuana problem 
scores significantly decreased from 3.1 (SD=2.5) during the baseline period to 0.9 
(SD=1.0) during the marijuana abstinence period (t(27)=6.24, p<0.01), and then increased 
to 1.9 (SD=2.6) during the return-to-baseline period (t(27)=-2.73, p=0.01).  Furthermore, 
mean marijuana problem scores were significantly greater during the baseline period than 
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during the return-to-baseline period (t(27)=2.83, p<0.01).   All scores of marijuana 
problem subscales significantly changed across the three periods (physical problems: 
p<0.01; psychological problems: p<0.01; and social problems: p<0.01), with all subscale 
scores significantly decreasing from the baseline period to the marijuana abstinence 
period and all except psychological problems increasing from abstinence to the return-to-
baseline period. 
   
Alcohol Substitution Effect 
 Table 4 shows outcomes related to the alcohol substitution effect.  Self-reported 
alcohol use showed a trend towards changing across the three periods of the study 
(p=0.06), accounting for 10.1% of the variance.  Alcohol use significantly increased from 
a mean of 2.6 drinks/day (SD=1.0) during the baseline period to 3.0 drinks/day (SD=1.0) 
during the marijuana abstinence period (t(27)=-2.29, p=0.03), a 15% increase.  Alcohol 
use then significantly decreased to 2.5 drinks/day (SD=1.3) during the return-to-baseline 
period (t(27)=2.33, p=0.03), a 17% decrease.   
 Changes in alcohol drinks/day from the baseline to the marijuana abstinence 
period across participants ranged from a decrease of 42% to an increase of 143%, 
suggesting significant between-person variability in the alcohol substitution effect. 
Eleven of the 28 participants (39%) decreased their alcohol use by 2%-42%, while 9 




 The percentage of days of consuming at least one alcohol drink in each period 
was significantly greater in the marijuana abstinence period (M=77%, SD=16%) 
compared to the two baseline periods (M=69%, SD=19%; p<0.01).  The percent of binge-
drinking episodes was marginally greater in the marijuana abstinence period (M=27%, 
SD=14%) than the two baseline periods (M=23%, SD=14%, p=0.05). When only days 
that participants consumed at least one drink of alcohol were examined, alcohol use did 
not significantly change across the three periods (p=0.30). When weekday and weekend-
day alcohol use were examined separately, both showed similar trends towards increasing 
alcohol use during marijuana abstinence but neither trend was statistically significantly 
(weekday: p=0.32, 13% increase; weekend-day: p=0.17, 17% increase). 
 Alcohol craving scores significantly changed across the three periods of the study 
(p<0.01), accounting for 19.6% of the variance.  Mean alcohol craving scores 
significantly increased from the baseline period (M=6.1 [SD=3.4]) to the marijuana 
abstinence period (M=7.2 [SD=4.1]; t(27)=-2.70, p=0.01), and mean scores then 
significantly decreased from abstinence to the return-to-baseline period (M=5.5 [SD=3.4]; 
t(27)=3.41, p<0.01).   
 Alcohol problem scores did not significantly change across the three periods of 
the study (p=0.28).  However, in an individual analysis of participants’ change in alcohol 
problem scores, one participant reported a substantial increase in alcohol problems from 
the baseline period to the marijuana abstinence period.  This individual reported a mean 
of 0.3 alcohol problems in the baseline period but then reported 6 alcohol-related 
problems after one week of abstaining from marijuana.  Throughout visits during the 
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second abstinence week and the return-to-baseline period, he reported a mean of 2.0 
alcohol-related problems. 
 All but one of the 252 BAL samples collected at laboratory visits were negative 
for alcohol.  The one positive BAL sample (BAL=0.01) occurred at the last visit of the 
baseline period, and the participant who submitted this breath sample reported that he had 
consumed one beer shortly before his visit.  He was required to remain at the laboratory 
until his BAL was negative for alcohol. 
  
Moderators of the Alcohol Substitution Effect 
 Period and diagnosis of past alcohol abuse/dependence significantly interacted to 
predict alcohol substitution (F(2,25)=9.81, p<0.01), accounting for 44% of the variance 
(Figure 4).  The seven participants with a diagnosis of past alcohol abuse or dependence 
(but currently non-abstinent from alcohol) significantly increased their mean alcohol 
drinks/day from 2.5 (SD=1.3) during the baseline period to 3.7 (SD=1.2) during the 
marijuana abstinence period, a 52% increase (t(6)=-5.18, p<0.01).  They did not 
significantly decrease their mean alcohol drinks/day from the marijuana abstinence 
period to the return-to-baseline period (M=3.5, SD=1.1, t(6)=0.61, p=0.57).  The 21 
participants without this diagnosis reported a minimal increase in mean alcohol 
drinks/day from 2.6 (SD=1.0) during the baseline period to 2.7 (SD=0.8) during the 
marijuana abstinence period, a 3% increase (t(20)=-0.46, p=0.65) but a significant 
decrease (19%) from the marijuana abstinence period to the return-to-baseline period 
(M=2.2, SD=1.2, t(20)=2.36, p=0.03). 
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 Period and alcohol use during the baseline period significantly interacted to 
predict alcohol substitution (F(2,25)=5.80, p<0.01), accounting for 32% of the variance.  
Those participants who consumed fewer than the median number of drinks/day during the 
baseline period were more likely to increase their alcohol use in the marijuana abstinence 
period (M=1.7 [SD=0.4] in the baseline period to M=2.6 [SD=0.9] in the marijuana 
abstinence period, t(11)=-3.99, p<0.01, a 53% increase) than those who drank more than 
the median number of drinks/day (M=3.3 [SD=0.7] in the baseline period to M=3.2 
[SD=1.0] in the abstinence period, t(15)=0.23, p=0.82, a 3% decrease). 
 Period and diagnosis of current cannabis dependence vs. abuse did not 
significantly interact to predict alcohol substitution (F(2,25)=2.00, p=0.16), nor did 
period and diagnosis of past drug dependence vs. no diagnosis (F(2,25)=0.07, p=0.92).  
There were no significant interactions between period and any demographic 
characteristics (sex: F(2,25)=1.30, p=0.29; age: F(2,25)=1.99, p=0.16); race: 
F(2,25)=0.22, p=0.80); education: F(2,25)=0.59, p=0.56); employment: F(2,25)=0.61, 
p=0.55). Period did not significantly interact with any psychological characteristics 
during the baseline period to predict alcohol substitution, including marijuana withdrawal 
discomfort (F(2,25)=0.37, p=0.70), marijuana craving (F(2,25)=0.48, p=0.62), marijuana 
problems (F(2,25)=0.21, p=0.81), alcohol craving (F(2,25)=0.46, p=0.64), alcohol 




Correlates of the Alcohol Substitution Effect 
 The change in mean alcohol drinks/day from the baseline period to the marijuana 
abstinence period significantly correlated with the change in mean marijuana withdrawal 
discomfort scores between these two periods (Pearson r=0.47, p=0.01).   The change in 
mean alcohol drinks/day also significantly correlated with the change in mean alcohol 
craving scores (Pearson r=0.41, p=0.03) and with the change in mean alcohol problem 
scores (Pearson r=0.50, p<0.01) (Figure 5).  The change in mean alcohol drinks/day did 
not significantly correlate with the change in mean marijuana problem scores (Pearson 
r=-0.03, p=0.89).    
  
Time Course of the Alcohol Substitution Effect 
 The expected number of alcohol drinks/day based on participants’ alcohol use 
during weekday and weekend-days in the baseline and return-to-baseline periods were 
compared to that observed in the abstinence period.  As Figure 6 shows, greater than 
expected increases in alcohol use occurred on 8 of the 13 days of the abstinence period 
(62%).  The most substantial increase in alcohol use occurred on the second day of the 
marijuana abstinence period (mean of 1.45 alcohol drinks more than expected), and 
consistent increases were observed on days 5 – 9 of the abstinence period (Tuesday 
through Saturday).  Decreases were observed on days 3 (Sunday), 10 (Sunday), and 11 
(Monday).  After the second day of abstinence, the alcohol substitution effect did not 




Mood Disturbance  
 Mood disturbance scores significantly changed across the three periods of the 
study (p<0.01), accounting for 20.5% of the variance (Table 5).   Overall mean POMS 
scores did not significantly change from the baseline period to the marijuana abstinence 
period (t(27)=0.06, p=0.96), but they did significantly decrease from the abstinence 
period to the return-to-baseline period (t(27)=3.64, p<0.01), indicating decreased mood 
disturbance over time.  Similar non-significant differences between baseline and 
marijuana abstinence but significant differences between abstinence and return-to-
baseline occurred for tension subscale scores (t(27)=3.31, p<0.01), depression subscale 
scores (t(27)=3.23, p<0.01), and anger subscale scores (t(27)=3.07, p<0.01).  Fatigue 
subscale scores significantly changed across the three periods of the study (p<0.01), 
accounting for 24.6% of the variance.  The mean fatigue subscale score significantly 
decreased from the baseline period to the marijuana abstinence period (t(27)=2.23, 
p=0.04), and the mean fatigue subscale score marginally decreased again from the 
abstinence period to the return-to-baseline period (t(27)=2.06, p=0.05).  Confusion 
subscale scores significantly changed across the three periods of the study (p<0.01), 
accounting for 16.6% of the variance.  The mean confusion subscale score significantly 
decreased from the baseline period to the marijuana abstinence period (t(27)=2.53, 
p=0.02), but the mean confusion score of the abstinence period did not significantly differ 
from that of the return-to-baseline period (t(27)=1.14, p=0.26).  Mean vigor subscale 
scores did not significantly change across the three periods of the study (p=0.26). 
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Substitution of Other Substances 
 Although seven participants were current smokers at the initial assessment, 13 
participants smoked at least one cigarette during the baseline period.  Of these 13 
participants, one participant initiated and sustained a quit attempt during the marijuana 
abstinence period.  Of the remaining 12, self-reported cigarettes/day did not significantly 
change across the three study periods (p=0.28) (Table 6).  Mean carbon monoxide levels 
did not significantly change across the three study periods (p=0.49).  Surprisingly, 10 of 
the 12 smokers submitted urine samples that were negative for cotinine throughout the 
study; it is likely that most samples were negative for cotinine because its cut-off was 
high (i.e., 500 ng/mL; Dominion Diagnostics, Providence, RI) and because participants 
did not smoke cigarettes on a daily basis.  Craving for cigarettes showed a trend toward 
changing across the three study periods (p=0.13); although craving did not significantly 
change from the baseline period to the marijuana abstinence period, it significantly 
decreased from the marijuana abstinence period to the return-to-baseline period 
(marijuana abstinence period: M=12.0, SD=2.6; return-to-baseline period: M=10.8, 
SD=1.6; t(11)=2.7, p=0.02).  Craving subscales related to relief from negative affect and 
desire to smoke did not significantly change across the three periods (relief from negative 
affect: p=0.14; desire to smoke: p=0.16).  Of the 15 participants who did not smoke any 
cigarettes during the baseline period, 9 did not smoke any during the marijuana 
abstinence period.  However, three non-smoking participants during baseline smoked 1-2 
cigarettes, two smoked 6-7 cigarettes, and one smoked 16 cigarettes during abstinence.   
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 All 28 participants consumed at least one caffeinated drink (i.e., coffee, tea, or 
soda) during the baseline period; thus, all were retained in analyses related to caffeine.  
Mean total number of caffeinated drinks/day did not significantly change across the three 
periods of the study (p=0.46).   
 Eleven participants used illicit drugs other than marijuana during the study: three 
used them only during baseline or return-to-baseline; four participants used them on one 
day of the baseline period and one day of the marijuana abstinence period; one used them 
on one occasion during abstinence only; and three participants used them on one day 
during baseline and multiple days during abstinence.  Of these latter three participants, 
two used illicit drugs twice during marijuana abstinence, and one used them four times 




Summary of Results 
 Results indicate that alcohol substitution occurred during marijuana abstinence. 
Although substitution of cigarettes, caffeine, and non-marijuana illicit drugs did not 
occur, this may be due to methodological limitations (see below).  Results also indicate 
that individuals with a diagnosis of past alcohol abuse or dependence substituted alcohol 
to a greater degree than those without this past history.  Finally, they indicate that 
increases in alcohol drinks/day significantly and positively correlated with increases in 
marijuana withdrawal discomfort scores and with increases in alcohol craving scores 
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from the baseline to the marijuana abstinence period.  Problems related to alcohol did not 
significantly increase from baseline to marijuana abstinence.   
 
Alcohol Substitution 
 In this study, daily marijuana users who met diagnostic criteria for cannabis 
dependence or abuse reported a 15% increase in their alcohol consumption from a one-
week period of using marijuana as usual to a two-week period of abstaining from 
marijuana. The alcohol substitution effect appeared to be due to an increased percentage 
of days consuming at least one drink of alcohol from baseline to marijuana abstinence.  
Non-significant trends for increases in binge-drinking episodes and increased alcohol 
drinks/day on weekends were observed, but power to detect these differences may have 
been low.  Alcohol problem scores did not significantly increase from baseline to 
marijuana abstinence, but they did significantly correlate with increases in alcohol use 
and there was some evidence for an increase in alcohol problems in a minority of regular 
marijuana users.  Although the two-week marijuana abstinence period may not have been 
lengthy enough to result in a clinically-significant increase in alcohol problems, there was 
not a trend for alcohol problems to worsen as the abstinence period continued.  
Nonetheless, given the increase in alcohol use and the positive correlation between 
increased alcohol use and increased alcohol problems, these results suggest that clinicians 
should regularly assess for alcohol use and alcohol-related problems when treating 
marijuana users who continue to use alcohol during marijuana cessation.  Even without a 
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significant increase in alcohol consumption during marijuana cessation, alcohol problems 
can still worsen (Stephens et al., 2000).  
 When individuals stop use of one substance, they might substitute another 
pharmacologically-similar substance or one that antagonizes withdrawal symptoms of the 
originally-used substance.  Although marijuana and alcohol belong to different drug 
classification classes (i.e., hallucinogens vs. sedatives) and have different chemical 
structures, they both increase dopamine release in the nucleus accumbens (Boileau et al., 
2003; Tanda & Goldberg, 2003), part of the neurobiological pathway of the 
mesocorticolimbic system that is implicated in drug reinforcement (Gardner and 
Lowinson, 1991; Koob, 1992). This common enhancement of brain reward mechanisms 
may explain the shared behavioral effects of marijuana and alcohol. For example, 
individuals report feelings of sedation, relaxation, euphoria, and relief from anxiety, as 
well as disinhibition, after using marijuana and alcohol (Julien, 2001; Rang, Dale, Ritter 
& Moore, 2003).  Thus, individuals who use marijuana daily and alcohol moderately may 
use alcohol on more days when abstaining from marijuana in order to achieve the 
subjective feelings listed above that are related to intoxication.  It is also possible that 
conditioning plays a role in the substitution of alcohol for marijuana.  Because most 
marijuana users tend to use marijuana and alcohol simultaneously (i.e., at the same time; 
Midanik, Tam & Weisner, 2007), use of one substance could act as a cue to elicit the use 
of another.  These findings are consistent with the expectation of current marijuana users 
themselves: 31% of Australian survey respondents who currently use marijuana indicate 
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they would consume more alcohol if cannabis became harder or more expensive to obtain 
(Jones & Weatherburn, 2001). 
 
Variability of the Alcohol Substitution Effect 
 There was substantial between-person variability in the degree of alcohol 
substitution.  In particular, regular marijuana users with a diagnosis of past alcohol abuse 
or dependence substituted alcohol to a greater degree than those without this diagnosis 
(52% vs. 3% increase).  This finding echoes findings of prior studies that substitution can 
be especially prominent for particular subgroups of substance users (Aubin et al., 1999; 
Bovasso & Cacciola, 2003; Gossop et al., 2003; Harris et al., 2000) and is especially 
important for the substantial percent of heavy marijuana users with a lifetime diagnosis of 
alcohol abuse or dependence (Kouri, Pope, Yurgelun-Todd & Gruber, 1995).  
Participants in the current study had been in remission from alcohol abuse or dependence 
for at least one year, yet their risk for reverting to heavy alcohol use appears to still be 
high.  Importantly, this subgroup did not decrease their alcohol use during the return-to-
baseline period, but they resumed their marijuana use to near-baseline levels after 
marijuana abstinence ended.  The lack of decrease in alcohol use in combination with a 
return to marijuana use suggests that these individuals may be at high risk for polydrug 
abuse.  On the other hand, participants were only examined for one week after resuming 
marijuana use, so this subgroup might require more time to decrease their alcohol use.  
The finding that regular marijuana users with a diagnosis of past alcohol abuse or 
dependence drive the alcohol substitution effect has significant implications for 
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marijuana treatment.  First, clinicians who treat individuals for marijuana-related 
problems should carefully monitor alcohol use in those with a past history of alcohol 
problems.  Second, this subgroup of daily marijuana users should be apprised of the 
possibility of increasing their alcohol use upon marijuana cessation.  Third, this subgroup 
might need additional interventions related to their alcohol use.  Fourth, although 
equivocal findings have been reported regarding whether a lifetime history of alcohol 
dependence impairs smoking cessation (Breslau, Peterson, Schultz, Andrewski & 
Chilcoat, 1996; Covey, Hughes, Glassman, Blazer & George, 1994; DeSoto, O’Donnell 
& DeSoto, 1989; Hughes, 1993; Hughes, Callas, & High Dose Study Group, 2003; 
Sobell, Sobell & Toneatto, 1992), it remains to be seen whether this lifetime history 
impairs marijuana cessation.   
 Another subgroup that especially substituted alcohol was comprised of those 
individuals who consumed alcohol at levels below the median number of drinks/day 
during the baseline period (53% increase in those who drank less the median number of 
drinks/day during baseline vs. 3% decrease in those who drank more than the median 
number).   It is possible that those with higher levels of alcohol use during the baseline 
period were aware that their use was high and thus consciously limited their alcohol use 
during the marijuana abstinence period.   Conversely, those with lower levels of alcohol 
use during the baseline period may not have been concerned about their drinking and thus 
did not consciously limit their alcohol use.  This finding suggests that marijuana users 
who are also moderate alcohol drinkers should be advised before initiating marijuana 
abstinence that although their alcohol use might not be problematic, they are still at high 
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risk for increasing their alcohol use and should closely monitor their drinking during 
abstinence.  
 
Possible Mediators of the Alcohol Substitution Effect 
 Although the sample size prohibited formal mediational tests, the strong 
correlations between alcohol consumption and marijuana withdrawal discomfort scores 
and alcohol craving scores indicate that these are important factors related to the alcohol 
substitution effect.  Increases in alcohol drinks/day correlated with increases in marijuana 
withdrawal discomfort scores and increases in alcohol craving scores but not with 
increases in marijuana craving scores.  The significant increase in marijuana withdrawal 
discomfort scores from baseline to marijuana abstinence supports the validity of the 
marijuana withdrawal syndrome upon marijuana cessation (Budney, Hughes, Moore & 
Vandrey, 2004), and the correlation between these scores and increases in alcohol 
consumption adds evidence to its clinical significance.  Consistent with this, in other 
studies using retrospective reports, marijuana users stated that they have used alcohol and 
other substances to relieve the discomfort associated with marijuana withdrawal 
(Copersino et al., 2006b), suggesting that the marijuana withdrawal syndrome is severe 
enough to warrant action to minimize symptoms and their associated distress.  Perhaps 
regular marijuana users consume alcohol to blunt their mood and thus manage the 
withdrawal symptom of irritability (Budney et al., 2003).  They may also use more 
alcohol to aid in falling asleep, as sleep problems are another commonly-reported 
marijuana withdrawal symptom (Budney et al., 2003).  The correlation between alcohol 
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increases and marijuana withdrawal discomfort increases also suggests that alcohol 
substitution should abate as withdrawal abates over time.  Most marijuana withdrawal 
symptoms discontinue after 14 days (Budney et al., 2003), so if withdrawal were driving 
the alcohol substitution effect, the effect should discontinue after 14 days.   
 The alcohol substitution effect’s correlation with alcohol craving indicates that the 
increase in alcohol consumption may not be sufficient to relieve all of the increase in 
alcohol craving during marijuana abstinence.  It also suggests that unavailability of one 
substance can increase craving or urge for another substance; for example, nicotine 
deprivation increases the urge to drink alcohol (Palfai, Monti, Ostafin & Hutchison, 
2000).  Surprisingly, marijuana craving scores did not significantly increase from 
baseline to marijuana abstinence, possibly because participants suppressed their craving 
for marijuana.  In a previous laboratory-based study, when participants were instructed to 
suppress their urge for alcohol, they increased the intensity of their cigarette smoking 
(i.e., took more puffs from cigarettes) (Palfai, Colby, Monti & Rohsenow, 1997).  Thus, 
suppression of craving or urge for one substance that is being controlled can increase the 
use of an associated substance that is not being controlled.  Furthermore, drug availability 
may be a necessary condition for craving (Juliano & Brandon, 1998), and participants in 
the current study were aware that they were not permitted to use marijuana during the 
abstinence period. Also, perhaps the lack of a significant increase in marijuana craving 
was due to the transformation of the 7-point Likert craving scale into a dichotomous 




Substitution of Other Substances 
 Although regular marijuana users substituted alcohol during marijuana cessation, 
they did not appear to substitute other substances.  Overall, in the current study, there was 
no consistent evidence of significant cigarette substitution, but a minority of participants 
(20% of nonsmokers during the baseline period) did initiate new cigarette use during 
marijuana abstinence.  This percentage is similar to that found for initiation of cigarette 
use during alcohol abstinence in Project MATCH (Friend & Pagano, 2004).  Individuals 
might substitute or initiate cigarettes to experience sensory aspects that are associated 
with smoking marijuana, such as the sensation of smoke in the lungs.   Additionally, 
because many individuals smoke both cigarettes and marijuana (Moore & Budney, 2001; 
SAMHDA, 2005; Stephens, Roffman & Simpson, 1993), they might be subject to the 
same conditioning cues as those related to using alcohol and marijuana simultaneously.  
Nicotine, the psychoactive ingredient in cigarettes, is a stimulant, and although its effects 
are not similar to the effects of marijuana, its stimulatory effects might counteract 
withdrawal symptoms, such as irritability (Budney et al., 2003).   Because the 
participants in this study are not regular or dependent smokers, cigarette substitution 
might appear in heavier, more dependent cigarette smokers.   
 Individuals in this study did not substitute non-marijuana illicit drugs during 
marijuana cessation.  Three participants increased their use of other illicit drugs, and one 
participant initiated non-marijuana illicit drug use (i.e., inhalant use) during marijuana 
abstinence.  However, none of these increases was clinically-significant.  Only one of 
these four individuals met criteria for a diagnosis of past substance abuse or dependence: 
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the individual who initiated inhalant use during the marijuana abstinence period met 
criteria for past opioid dependence.  It is possible that different outcomes could be 
observed with a larger sample of those with a diagnosis of past substance abuse or 
dependence.   
 Finally, individuals did not substitute caffeine for marijuana.  This trend is not 
unexpected, as caffeine and marijuana do not share many psychoactive properties, and 
individuals probably do not use marijuana and caffeine simultaneously.  Thus, the drug 
substitution effect in this study is limited to alcohol.  
 
Limitations 
 Findings from the present study may be tempered by possible limitations on the 
external validity of the study, i.e., the exclusion of individuals who used marijuana less 
than five times per week, did not meet diagnostic criteria for current cannabis abuse or 
dependence, were light or heavy alcohol users, met diagnostic criteria for current alcohol 
or non-marijuana substance abuse or dependence, or were trying to stop their marijuana 
use. Although participants reported at study entry that they usually consumed a mean of 
about 10 alcoholic drinks/week, they consumed a mean of 18 drinks/week during the 
baseline period.  Because their weekly alcohol use is higher than moderate drinking 
guidelines (Sanchez-Craig et al., 1995), this study’s findings may apply more to heavier 
drinkers than moderate drinkers.  While individuals with marijuana use patterns similar to 
those who seek treatment for marijuana-related problems were targeted for inclusion in 
this study, the sample differs from treatment-seekers (The Marijuana Treatment Project 
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Research Group, 2004) by being younger and more likely to be male and Caucasian.   
These differences may limit the generalizability of this study’s findings.   
 There were also limitations related to internal validity. Alcohol use was not 
biochemically verified, but participants had no incentive to falsify their self-reports of 
alcohol use.  Furthermore, they provided their self-report of alcohol use via voicemail; 
this type of confidential and impersonal system might increase the accuracy of self-report 
(Moskowitz, 2004).  Importantly, the criteria for biochemical verification of marijuana 
abstinence could be said to be too lenient.   
 Perhaps the most significant limitation is that the findings of this study do not 
completely negate the concern about using alcohol or other substances during marijuana 
abstinence.  While alcohol substitution and some cigarette initiation were observed in this 
study, it is not known if these increases in other substances undermine the ability to 
abstain from marijuana.  It is possible that even without an increase in other substances, 
continued use of secondary substances could impair the ability to initiate or maintain 
abstinence from the primary drug of abuse.    
 
Strengths 
 A significant strength of this study is its methodology.  First, the use of a within-
subjects design with baseline, experimental, and return-to-baseline periods confers high 
experimental validity.  Second, in contrast to previous studies of marijuana cessation, 
alcohol use was examined prospectively and on a daily basis, allowing for a detailed 
picture of the time course of alcohol substitution.  Third, the collection of multiple self-
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report measures repeatedly during the study allowed for examination of specific patterns 
of alcohol use and of possible moderators and mediators of the alcohol substitution effect.  
Fourth, by recruiting individuals who were not trying to quit marijuana, contamination of 
outcomes due to voluntary restrictions on alcohol use to aid in marijuana abstinence that 
may cause false negative results were avoided.  Other strengths include the compliance of 
the majority of recruited participants with the 2-week period of marijuana abstinence and 
the biochemical verification of abstinence.   Among those who completed the study, there 
was very little missing data.  
 
Future Studies 
 Replication Tests 
 Because this is one of the first studies directly examining drug substitution, 
rigorous replication tests are needed.  First, a 2-week marijuana abstinence period may 
not have been sufficiently long for individuals to develop alcohol problems, so with an 
extended marijuana abstinence period, whether alcohol problems develop over time can 
be understood.  Second, building from the current ABA design, a study with an ABAC 
design is possible. The “C” period could entail abstinence from both marijuana and 
alcohol to determine if marijuana and alcohol withdrawal symptoms and craving are 
additive.  Additionally, many treatment programs recommend this type of abstinence 
(i.e., from all substances), so it is important to understand if this recommendation is 
problematic. Third, with a larger sample size, formal mediational tests would be possible. 
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 Finally, marijuana users actively trying to stop their marijuana use could be 
studied to determine whether drug substitution interferes with the ability to quit 
marijuana.  People who use more than one substance regularly are at higher risk for poor 
treatment retention and abstinence rates, as well as relapse to substance use (Hartel et al., 
1995; Moore & Budney, 2001; Sobell, Sobell & Kozlowski, 1995; Stuyt, 1997; 
Wasserman et al., 1998), and drug substitution might worsen these problems (Friend & 
Pagano, 2005).   
  
 Drug Substitution in Different Subgroups 
 Given that drug substitution may be limited to certain subgroups of substance 
users, studies similar to the current one but with different subgroups can be undertaken to 
further examine what these subgroups are.  Similar studies can be conducted with 
individuals who use marijuana daily but do not consume any alcohol or with individuals 
who consume more alcohol than moderate alcohol drinking guidelines suggest (Sanchez-
Craig et al., 1995).  By studying these different subgroups, it can be seen whether 
marijuana abstinence leads alcohol abstainers to initiate alcohol use or if it causes even 
more alcohol consumption in heavy drinkers.  The same methodology with marijuana 
treatment-seekers who are also moderate alcohol drinkers can be employed; findings that 
are similar to those with non-treatment-seekers in the current study would provide 
external validity for the drug substitution effect.  Expectations of treatment-seekers about 
whether they think their alcohol use will increase and whether they believe they need to 
be concerned about this possible increase could be a priori assessed.    
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 Although negative conclusions regarding substitution of cigarettes, caffeine, and 
non-marijuana illicit drugs during marijuana abstinence were obtained in this study, it is 
unclear whether different conclusions would be obtained with different populations.  A 
study of cigarette substitution with regular marijuana users who are also regular (i.e., at 
least 10 cigarettes/day) and dependent smokers could be conducted.  Such a study has 
been accomplished, but individuals in this study were instructed to not change their use 
of cigarettes during marijuana abstinence (Vandrey, Budney, Hughes & Liguori, 2008).  
A study of non-marijuana illicit drug substitution with regular marijuana users with a past 
history of illicit substance dependence could also be conducted.    
 Finally, negative conclusions regarding an increase in mood disturbance scores 
from the baseline to the marijuana abstinence period were obtained, but these participants 
did not report any significant mood problems (i.e., current mood or anxiety disorders) at 
study entry.  Thus, a study of drug substitution in individuals with current mood problems 
could be conducted to see if mood disturbance scores increase from baseline to marijuana 
abstinence and whether these increased mood problems result in even greater alcohol 
substitution or vice versa, i.e., whether alcohol substitution worsens or improves mood.  
This type of study would increase the external validity of the substitution effect, given 





 Interventions Related to the Alcohol Substitution Effect 
 Because alcohol use increases during marijuana abstinence, the efficacy of 
interventions to prevent an increase in alcohol use during marijuana treatment could be 
examined. Kahler and colleagues (Kahler, Metrik, LaChance, Ramsey, Abrams, Monti, & 
Brown, 2008) compared the efficacy of an alcohol-related intervention in conjunction 
with smoking cessation treatment to standard smoking cessation treatment alone in heavy 
drinkers.  Those who received interventions related to both cigarette and alcohol use 
reported fewer drinks per week and greater smoking abstinence than did those in standard 
smoking cessation treatment, but the effects related to smoking were mostly evident soon 
after the quit date and were essentially absent by 16 weeks.  On the other hand, in some 
studies concurrent alcohol and smoking treatment worsened alcohol-related outcomes in 
comparison to a delayed smoking intervention after alcohol treatment (Joseph, 
Willenbring, Nugent & Nelson, 2004).  Thus, integrating additional alcohol-related 
interventions to marijuana cessation treatment appears feasible, but timing of the 
interventions might need to be examined first.   
 
 Other Studies of Drug Substitution 
 The above-suggested studies have addressed what occurs during marijuana 
cessation.  Studies examining other drug substitutions can also be undertaken using the 
same methods.  Several studies have already investigated whether alcohol use increases 
during smoking cessation (Carmelli, Swan & Robinette, 1993; Murray, Cribbie, Istvan & 
Barnes, 2002; Murray, Istvan & Voelker, 1996) and whether smoking increases after 
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alcohol abstinence (Gulliver et al., 2000), but whether marijuana use increases during 
smoking cessation or during alcohol cessation can be examined.  Substitution of other 
substances should be examined prospectively and with precise measurement (i.e., daily 
assessments), and initiation of other substances should also be assessed.  
 
Clinical Implications 
 If these results are replicated and if increased alcohol use during marijuana 
abstinence were shown to cause problems or interfere with marijuana abstinence, then 
clinicians treating marijuana users should continue to recommend complete abstinence 
from all substances.  In order to assist individuals in abstaining from all substances, 
clinicians ought to deliver interventions that either separately address marijuana and 
alcohol use or interventions that address addictive behaviors in general.  They might also 
assess for initiation of new substances, given some evidence for cigarette initiation in the 
current study.  However, if individuals abstain only from marijuana, clinicians should be 
aware that continued alcohol use, even without a significant increase, might undermine 
marijuana abstinence.     
 
Summary 
 This study provides empirical validation of the clinical notion of drug 
substitution, although the substitution effect was restricted to alcohol use during 
marijuana abstinence, to the subgroup of daily marijuana users with a past history of 
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alcohol abuse or dependence, and to the subgroup of daily marijuana users with low 
alcohol use during the baseline period.  These findings suggest that clinicians’ concerns 
about drug substitution may be valid, but they need to be replicated in individuals who 
seek treatment for marijuana problems.  If replicated, then whether alcohol substitution 
interferes with the ability to quit marijuana or if increased alcohol use causes problems in 
its own right needs to be determined.  If so, this would be important empirical support for 
the clinical practice of recommending abstinence from all substances.  If not, then not 
insisting on abstinence from other drugs could remove an important barrier to entering 
















Table 1. Power Analysis. 
Within-subject 
Correlation 




0.6 30% 80% 53 
0.6 50% 80% 21* 
0.8 30% 80% 28* 
0.8 50% 80% 12* 
 
Note.  Within-subject correlations of alcohol consumption were derived from data from 
Budney et al. (2003) and from a preliminary study of tobacco smokers (Peters, Hughes, 
Callas & Solomon, 2007). 
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Table 2.  Participant Characteristics. 
Demographic Characteristics 
Age (M [SD]) 23.0 (3.4) 
Sex (% male) 75 
Race (% non-Hispanic Caucasian) 93 
Marital status (% unmarried) 100 
Employment (% full-time) 36 
Education (% completed high school) 100 
Substance Use Characteristics - History 
Age first tried marijuana (M [SD]) 14.9 (1.5) 
Age first used marijuana regularly (M [SD]) 17.1 (2.6) 
Age first tried alcohol (M [SD]) 14.2 (1.6) 
Age first used alcohol regularly (M [SD]) 17.8 (1.7) 
Met DSM-IV criteria for past alcohol abuse or dependence (%) 25 
Met DSM-IV criteria for past non-cannabis substance dependence (%) 7 
Substance Use Characteristics - Current 
Days/week currently use marijuana (M [SD]) 6.3 (0.8) 
Sessions/day currently use marijuana (M [SD]) 2.7 (2.2) 
Standard alcohol drinks/week (M [SD]) 9.7 (4.7) 
Binge-drinking days/month (M [SD]) 3.3 (3.0) 
Caffeinated drinks/day (M [SD]) 2.3 (1.6) 
Current cigarette smokers (%) 25 
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FTND score for current cigarette smokers (M [SD]) 1.1 (1.9) 
Note.  Characteristics are for 28 participants who completed the study and are included in 
data analysis.  DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, Fourth 





Table 3.  Outcomes Related to Marijuana Use. 
 Period  






















WDS  2.9 (2.9)a 5.1 (4.0)b 2.5 (2.7)a F(1.6,44.0)=15.26, 
p<0.01 








Craving      
      Overall  6.9 (2.5) 6.7 (2.7) 6.7 (2.8) F(2.0,52.7)=0.32, 
p=0.73 
      Compulsivity  0.9 (0.8) 1.0 (1.0) 0.9 (1.0) F(2,54)=0.07, 
p=0.94 
      Emotionality  3.0 (1.3) 3.2 (1.3) 3.2 (1.4) F(1.6,44.1)=1.33, 
p=0.27 




Purposefulness 1.7 (0.8) 1.4 (0.8) 1.5 (1.0) F(2,54)=1.27, 
p=0.29 
Problems      
      Overall  3.0 (2.5)a 0.9 (1.0)b 1.9 (2.6)c F(2,54)=16.63, 
p<0.01 
      Physical        1.3 (1.4)a 0.4 (0.6)b 0.9 (1.5)a F(1.9,50.7)=8.84, 
p<0.01 
      Psychological  0.9 (0.9)a 0.4 (0.6)b 0.5 (0.8)b F(1.9,50.7)=9.44, 
p<0.01 
      Social  0.8 (0.8)a 0.1 (0.4)b 0.5 (0.8)a F(2.0,53.7)=10.9, 
p<0.01 
 
Note.  Data presented as means and standard deviations.  F-values are presented from 
Huynh-Feldt tests of repeated-measures ANOVAs, p<0.05, with study period as the 
within-subjects factor. Different subscripted letters denote significant between-period 
differences from paired samples t-tests, p<0.05.  THCCOOH = 11-nor-9-carboxy-∆9-
tetrahydrocannabinol; WDS = Withdrawal Discomfort Score. 
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Table 4.  Outcomes Related to Alcohol Use. 
 Period  







Drinks/day 2.6 (1.0)a 3.0 (1.0)b 2.5 (1.3)a F(1.9,51.2)=3.02, 
p=0.06 
Drinks/day: days 
drank ≥ 1 drink  








2.0 (1.1) 2.3 (1.1) 2.1 (1.2) F(1.9,51.7)=0.59, 
p=0.40 
Percentage of days 
drank ≥1 drink 
69% (19%)a 77% (16%)b 68% (26%)a Z=-2.69, p<0.01 
Percentage of 
binge-drinking days 
23% (15%) 27% (14%) 23% (17%) Z=-1.96, p=0.05 
Craving  6.1 (3.4)a 7.2 (4.1)b 5.5 (3.4)a F(2.0,53.4)=6.56, 
p<0.01 





Note.  Data presented as means and standard deviations.  F-values are presented from 
Huynh-Feldt tests of repeated-measures analyses of variance (ANOVAs), with study 
period as the within-subjects factor. Z-values are presented from Wilcoxon signed ranks 
tests. Different subscripted letters denote significant between-period differences from 
paired samples t-tests, p<0.05, except with Wilcoxon signed rank tests, where the 
baseline and return-to-baseline periods were combined and contrasted with the marijuana 


















Table 5.  Outcomes Related to Mood Disturbance. 
 Period  




Baseline  Significance Testing  
Overall mood 
disturbance  
4.9 (7.8)a 4.8 (9.9)a 1.3 (7.6)b F(2.0,53.6)=6.96, 
p<0.01 
      Tension  1.7 (1.5)a 2.1 (2.2)a 1.1 (1.5)b F(1.7,44.5)=7.13, 
p<0.01 
      Depression  1.7 (1.9)a 1.8 (2.3)a 1.0 (1.8)b F(2.0,52.9)=4.91, 
p<0.01 
      Anger  1.4 (1.6)a 1.9 (2.6)a 0.6 (1.3)b F(1.7,46.3)=7.01, 
p<0.01 
      Fatigue  3.7 (2.4)a 2.9 (2.7)b 2.1 (2.2)c F(2.0,54.0)=8.79, 
p<0.01 
      Confusion  2.7 (1.5)a 2.3 (1.6)b 2.1 (1.5)b F(1.9,50.1)=5.36, 
p<0.01 
      Vigor  6.3 (3.2) 6.2 (3.5) 5.6 (3.4) F(2.0,53.5)=1.37, 
p=0.26 
 
Note. Data presented as means and standard deviations.  F-values are presented from 
Huynh-Feldt tests of repeated-measures ANOVAs, p<0.05, with study period as the 
within-subjects factor. Different subscripted letters denote significant between-period 
differences from paired samples t-tests, p<0.05. 
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Table 6.  Outcomes Related to Cigarette and Caffeine Use. 
 Period  











4.4 (4.6) 3.4 (3.4) 3.7 (3.7) F(1.4,14.8)=0.62, 
p=0.49 
Cigarette craving      
     Overall 12.8 (4.6) 12.0 (2.6) 10.8 (1.6) F(1.2,13.6)=2.53, 
p=0.13 
     Relief  4.7 (1.5) 4.3 (0.5) 4.1 (0.3) F(1.2,16.7)=2.39, 
p=0.14 
     Desire 6.8 (2.8) 6.5 (1.8) 5.7 (1.6) F(1.5,16.7)=2.11, 
p=0.16 
Caffeinated drinks/day 1.4 (1.0) 1.3 (0.7) 1.3 (0.7) F(1.6,42.4)=0.73, 
p=0.46 
 
Note.  Data presented as means and standard deviations.  F-values are presented from 
Huynh-Feldt tests of repeated-measures ANOVAs, p<0.05, with study period as the 
within-subjects factor.  12 participants who smoked at least one cigarette during the 
baseline period and did not abstain from cigarettes during marijuana abstinence were 
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retained in cigarette-related analyses.  28 participants who consumed at least one 
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312 screened by telephone 
67 eligible  245 ineligible 
18 not interested 
after telephone 
screen 




38 eligible after 
initial assessment 
2 not interested 36 enrolled and began the 
study 
29 completed 7 terminated 
1 omitted from data 
analysis 
28 used in final analysis 
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Figure 1.  Experimental timeline.  Tick marks represent each study day.  The marijuana 
abstinence period and return-to-baseline period overlap on day 21:  participants reported 
data related to marijuana abstinence when they visited their seventh laboratory visit on 
day 21; after leaving the laboratory they were allowed to use marijuana, so substance use 
data for day 21 represent the return-to-baseline period.  
 
Figure 2.  Participant recruitment and retention.   
 
Figure 3. Mean creatinine-normalized tetrahydrocannabinol (THCCOOH) levels.  The 
baseline level was collected one day before initiating marijuana abstinence, and the 
return-to-baseline level was collected 4 days after resuming marijuana use.  
 
Figure 4. Interaction between period and diagnosis of past alcohol abuse/dependence.  
Mean alcohol drinks/day are presented, and bars represent standard error of the mean.  
 
Figure 5. Correlates of the alcohol substitution effect.  Change scores represent the 
change between the baseline period and the marijuana abstinence period, with positive 




Figure 6.  Time course of the alcohol substitution effect.  Mean residual scores were 
calculated as the difference between observed alcohol drinks/day on each abstinence day 
and expected alcohol drinks/day based on participants’ baseline and return-to-baseline 
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